Transnasal Sphenopalatine Ganglia Block for Management of Chronic Migraines in Pediatric Patients
Status:
Withdrawn
Trial end date:
2021-02-05
Target enrollment:
Participant gender:
Summary
Single-center, open-label, pre-post treatment pilot study to evaluate the safety and
effectiveness of sphenopalatine ganglia blocks for the treatment of chronic migraine in the
pediatric population. 50 children with a diagnosis of chronic migraines will undergo a series
of three transnasal sphenopalatine ganglia blocks to measure their effect on headache
frequency, headache intensity, headache duration, and use of headache medication.